Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
News|Articles|March 26, 2025
Poll Results: Ethics & Psychiatry in 2025
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- A survey among Psychiatric Times readers revealed insights into ethical perspectives within psychiatry, highlighting prevailing opinions and concerns among professionals.
- A new poll is assessing whether psychiatry is effectively addressing federal skepticism, inviting participation from the professional community.
How do your fellow clinicians feel about ethical quandaries in psychiatry? Find out here.
Advertisement
Earlier this month, we asked the readers of Psychiatric Times a few questions related to ethics and psychiatry. Here's how you all answered...
We also have another poll running right now, assessing whether you think psychiatry doing enough to address federal doubt of the field. Respond
If you are interested in writing on ethics or suggesting a topic, please email us at
Advertisement
Related to this article
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
3
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5